bpc 157 legal status fda Exciting news for peptides coming out of today's committee hearing! The Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- to the 503A Bulks List for use in compounding for fda restrictions on bpc-157 compounding

benzene ring(s) ) replacing O with S addition of a halogen ( F, Cl, Br, I ) Factors decreasing lipid solubility ( drug reabsorption in kidney tubules) - additions commonly produced by metabolism to enhance excretion - these groups increase hydrogen bonding with water ( hydrophilicity) Addition of: - COOH - OH - NH 2 - O-CH 3 - SO 4 2- - glucuronic acid Examples of Drugs with Significant First Pass Effect or Low Bioavailability Drug: Propranolol- ~26% Bioavailability because 75-85 % is metabolized by the liver before it can reach the circulation when taken orally

Together, these findings highlight the importance of ABCC1 status in predicting treatment outcomes, independently of HER2/ ERBB2

Current literature emphasizes mechanistic exploration rather than definitive biological outcomes

By enhancing angiogenesis: Nutrients and oxygen reach damaged tissues faster Inflammatory byproducts are cleared more efficiently Regeneration speed increases across soft tissue, joints, and muscle BPC-157 promotes angiogenesis and capillary density in damaged tissues through modulation of VEGF and endothelial nitric oxide synthase (eNOS). Sikiric et al., Regenerative Pharmacology 2